Sarepta Therapeutics (SRPT) Company Report

Sarepta Therapeutics reported full-year 2025 total revenues of $2.2 billion, an increase of 16% year-over-year, including $1.86 billion in net product revenue. The company exited 2025 with $954 million in cash and investments.
For 2026, the company provided net product revenue guidance of $1.2 billion-$1.4 billion for its approved therapies and reaffirmed its non-GAAP OpEx outlook of $800 million-$900 million. Q1 2026 revenue is expected to be flat to down 15% from Q4 2025.
CEO Doug Ingram announced his intention to retire as CEO by around the end of 2026, and a comprehensive search for his successor has been initiated.
ELEVIDYS received traditional approval for all ambulatory patients four and over. The company is implementing initiatives to address information deficits and patient/physician hesitation, with an expected impact on sales significantly in the second half of 2026.

2 days ago

Transcript

Sarepta Therapeutics Reports Q4 2025 Results, Provides 2026 Guidance, and Announces CEO Retirement

SRPT

Earnings

CEO Change

Guidance Update

Sarepta Therapeutics exited 2025 with a strong financial position, reporting $954 million in cash and investments and anticipating being cash flow positive and profitable on a non-GAAP basis in 2026.
The company provided 2026 net product revenue guidance of $1.2 billion-$1.4 billion and expects Q1 2026 revenue to be flat to down 15% from the prior quarter.
ELEVIDYS received traditional approval for all ambulatory patients aged four and over, with over 1,200 patients treated and positive three-year EMBARK data. Educational initiatives are expected to significantly impact sales in the second half of 2026 and into 2027.
CEO Doug Ingram announced his intention to retire by the end of 2026, citing family commitments related to myotonic dystrophy (DM1) diagnoses in his immediate family.
Preliminary data for the siRNA pipeline programs (DM1 and FSHD) are expected by the end of Q1 2026.

2 days ago

Transcript

Sarepta Therapeutics Announces Q4 and Full-Year 2025 Financial Results and Provides 2026 Guidance

SRPT

Earnings

Guidance Update

New Projects/Investments

Sarepta Therapeutics reported FY 2025 Total Revenues of $2.2 billion and a GAAP operating loss of ($700) million, with cash and investments totaling $954 million at year-end.
For Q4 2025, the company recorded Total Revenues of $443 million and a GAAP operating loss of ($412) million.
The company issued FY 2026 guidance, projecting Total Net Product Revenue between $1,200 million and $1,400 million and Total Collaboration, Contract Manufacturing and Royalty Revenues between $450 million and $550 million.
Sarepta anticipates presenting robust data from its neuromuscular portfolio at the 2026 MDA Meeting, including 3-year EMBARK results and safety analysis of ELEVIDYS clinical studies.
Key upcoming milestones include preliminary Phase 1/2 data for siRNA programs SRP-1003 (DM1) and SRP-1001 (FSHD) in 1Q 2026, and commencing dosing for SRP-1005 (Huntington's disease) in 1H 2026.

2 days ago

Presentation

Sarepta Therapeutics Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Announces CEO Retirement

SRPT

Earnings

Guidance Update

CEO Change

Sarepta Therapeutics concluded 2025 with a strong financial position, holding $954 million in cash and investments and projecting cash flow positive and non-GAAP profitability in 2026.
Total revenues for full year 2025 were $2.2 billion, marking a 16% year-over-year increase, with net product revenue contributing $1.86 billion.
For 2026, the company forecasts total net product revenue between $1.2 billion and $1.4 billion, alongside collaboration, contract manufacturing, and royalty revenues of $450 million to $550 million.
CEO Doug Ingram announced his plan to retire by the end of 2026, initiating a search for his successor.
ELEVIDYS generated $110 million in Q4 2025 revenue, with Q1 2026 revenue anticipated to be flat to down 15% from the prior quarter, as the impact of educational initiatives is expected to materialize in the second half of 2026.

2 days ago

Transcript

Sarepta Therapeutics Announces Q4 and Full-Year 2025 Financial Results and Key Developments

SRPT

Earnings

Product Launch

Guidance Update

Sarepta Therapeutics reported full-year 2025 total revenues of $2,198.2 million and a GAAP net loss of $(713.4) million, with diluted GAAP EPS of $(7.13), while fourth quarter 2025 total revenues were $442.9 million and GAAP net loss was $(412.2) million, with diluted GAAP EPS of $(3.93).
The company concluded 2025 with $953.8 million in cash, cash equivalents, restricted cash, and investments , and anticipates remaining profitable and cash-flow positive in 2026.
Significant corporate developments include the launch of ELEVIDYS in Japan in February 2026 , positive three-year results from the EMBARK study for ELEVIDYS in January 2026 , and the refinancing of $291.4 million of 2027 convertible notes in December 2025.
The U.S. FDA approved updated prescribing information for ELEVIDYS in November 2025, adding a boxed warning for serious liver injury and removing the non-ambulatory indication.

3 days ago

8-K

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

SRPT

Product Launch

New Projects/Investments

Sarepta Therapeutics announced the commercial launch of ELEVIDYS in Japan, making it the first gene therapy available in the country for Duchenne muscular dystrophy in eligible children aged 3 to less than 8 years.
Upon this first commercial sale in Japan, Sarepta is eligible to receive a $40 million milestone payment under its collaboration agreement with Roche.
Chugai Pharmaceutical Co., Ltd., a member of the Roche Group, is responsible for the commercialization of ELEVIDYS in Japan.

4 days ago

Press Release

Sarepta Therapeutics Announces Positive 3-Year Data for ELEVIDYS

SRPT

New Projects/Investments

Revenue Acceleration/Inflection

Sarepta Therapeutics announced positive 3-year topline functional results from Part 1 of the EMBARK (Study 9001-301) trial for ELEVIDYS (delandistrogene moxeparvovec-rokl) in boys with Duchenne Muscular Dystrophy (DMD) on January 26, 2026.
ELEVIDYS-treated patients remained above their baseline three years after treatment as measured by North Star Ambulatory Assessment (NSAA), with the functional gap compared to the external control group growing to a 4.39-point difference at Year 3.
The study demonstrated a statistically significant 73% slowing of disease progression as measured by Time to Rise (TTR) and a statistically significant 70% slowing of disease progression as measured by 10-meter walk run (10MWR).
The safety profile of ELEVIDYS remained consistent over three years, with no new safety signals observed.

Jan 26, 2026, 1:30 PM

Presentation

Sarepta reports significant three-year EMBARK data for ELEVIDYS

SRPT

Product Launch

New Projects/Investments

Sarepta announced positive three-year top-line results from the EMBARK Phase 3 pivotal trial for ELEVIDYS, demonstrating a dramatic shift in disease trajectory.
ELEVIDYS-treated patients, on average, remained above their baseline three years after treatment, as measured by the North Star Ambulatory Assessment (NSAA).
The therapy showed a 70% or greater reduction in disease progression relative to an external control group, based on time to rise and 10-meter walk/run assessments.
Key functional measures showed statistically significant differences at year 3, including a 4.39-point difference in NSAA (p=0.0002), a 6-second difference in time to rise (p<0.0001), and a 2.7-second difference in 10-meter walk/run (p=0.0039).
No new safety signals or treatment-related serious adverse events were observed in the third year, consistent with the known safety profile of ELEVIDYS.

Jan 26, 2026, 1:30 PM

Transcript

Sarepta Announces Three-Year Top-Line Results from ELEVIDYS EMBARK Trial

SRPT

Sarepta presented three-year top-line results from the EMBARK (ELEVIDYS Phase 3 pivotal trial), demonstrating a dramatic shift in disease trajectory for patients treated with ELEVIDYS.
ELEVIDYS-treated patients remained above baseline three years post-treatment, as measured by the North Star Ambulatory Assessment (NSAA), with a 4.39-point difference compared to the external control group (p-value = 0.0002).
The study showed a 70% or greater reduction in disease progression for ELEVIDYS-treated patients relative to the external control group, as measured by time to rise and 10-meter walk/run.
These statistically significant benefits persist and strengthen over time, creating a sustained and growing separation from the expected disease trajectory of Duchenne muscular dystrophy.
No new safety signals or treatment-related serious adverse events were observed in year three of the cohort.

Jan 26, 2026, 1:30 PM

Transcript

Sarepta Therapeutics Announces Positive Three-Year EMBARK Trial Results for ELEVIDYS

SRPT

Sarepta Therapeutics announced positive three-year top-line results from its EMBARK Phase 3 pivotal trial for ELEVIDYS, demonstrating a dramatic shift in disease trajectory for treated patients.
ELEVIDYS-treated patients remained above baseline on average in the North Star Ambulatory Assessment (NSAA) three years post-treatment, with a 4.39-point difference compared to the external control group (p=0.0002).
The trial demonstrated a 70% or greater reduction in disease progression for treated patients, measured by time to rise and 10-meter walk/run, with these benefits continuing to strengthen over time.
No new safety signals were observed in year three of the cohort, reinforcing the therapy's safety profile.

Jan 26, 2026, 1:30 PM

Transcript

Fintool News

In-depth analysis and coverage of Sarepta Therapeutics.

Corporate

Sarepta's ELEVIDYS Shows 70%+ Disease Slowing at 3 Years—Stock Surges 13% on Redemption Data

Jan 26

View all news

Earnings Transcripts

Quarterly earnings call transcripts for Sarepta Therapeutics.

Q4 2025

Feb 25, 2026

→

Q3 2025

Nov 3, 2025

→

Q1 2025

May 6, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Douglas Ingram say about margins?What are Sarepta Therapeutics's strategic priorities?How is Sarepta Therapeutics positioned vs competitors?How did Sarepta Therapeutics do last quarter?

Sarepta Therapeutics (SRPT)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q4 2024

Q4 2023

Executives

Douglas Ingram

Cristin Rothfuss

Ian Estepan

Louise Rodino-Klapac

Patrick Moss

Rachael Potter

Ryan Wong

Board Members

Claude Nicaise

Deirdre Connelly

Hans Wigzell

Kathryn Boor

M. Kathleen Behrens

Michael Chambers

Richard Barry

Stephen Mayo

Analyst Coverage

Biren Amin

Gil Blum

Joseph Schwartz

Tazeen Ahmad

Anupam Rama

Brian Abrahams

Brian Skorney

Michael Ulz

Ritu Baral

Andrew Tsai

David Hoang

Eliana Merle

Gavin Clark-Gartner

Huidong Wang

Konstantinos Biliouris

Kostas Biliouris

Kristen Kluska

Mitchell Kapoor

Sami Corwin

Brandon Folkes

Josh Bleichman

Leo Watson

Linda Tsai

Luke Sergott

Paige Thompson

Salveen Richter

Samantha Corwin

Sean Kim

Tommie Reerink

Tommy Smith

Uy Ear

William Pickering

Andreas Argyrides

Danielle Brill

Daniel Smith

Debjit Chattopadhyay

Gena Wang

John Kim

John Wolleben

Kevin

Kevin DeGeeter

Louise Chen

Michael Yee

Priyanka Grover

Robert Finke

Rohan

Ry Forseth

Tim Lugo

Yanan Zhu

Latest news

Fintool News

Sarepta's ELEVIDYS Shows 70%+ Disease Slowing at 3 Years—Stock Surges 13% on Redemption Data

Earnings Transcripts

Q4 2025

Q3 2025

Q1 2025